SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, today announced it
will be providing an update on its SIRPaFc immune checkpoint inhibitor program,
targeting the CD47 protein, at the 105th Annual Meeting of the American
Association for Cancer Research. The meeting will be held April 5-9, 2014 in San
Diego, CA. Details of the poster presentation, entitled "Cancer Immunotherapy
Targeting CD47: Wild Type SIRPaFc is the Ideal CD47-Blocking Agent to Minimize
Unwanted Erythrocyte Binding", are listed below:




Date: Wednesday April 9, 2014                                               
Time: 8:00 am - 12:00 pm (PT)                                               
Session ID: Immunology 11                                                   
Session Title: Immune Checkpoint Inhibition Abstract #: 5011                
Presenter: Dr. Robert Uger, Chief Scientific Officer                        
Location: Hall A-E, Poster Section 10, San Diego Convention Center          



The company will present data demonstrating that its wild type SIRPaFc fusion
protein, which binds effectively to CD47 with low nanomolar affinity, binds very
poorly to human red blood cells (RBCs) compared to both commercial anti-CD47
monoclonal antibodies (mAbs) and proprietary CD47-blocking agents. This striking
difference in binding was not seen with other cell types, including acute
myeloid leukemia (AML) tumor cells, suggesting it is an RBC-specific phenomenon.
In addition, the lack of significant SIRPaFc binding to erythrocytes is unique
to humans, since SIRPaFc bound strongly to mouse and non-human primate RBCs.
Overall, the data suggest that a wild type SIRPaFc fusion protein may be the
ideal CD47-blocking agent to reduce the potential antigen sink effect caused by
RBCs and to minimize hematological toxicity in patients, while maintaining
potent anti-tumor effects.


"Our results are consistent with independently publ ished reports documenting
differences in binding between CD47-specific antibodies and the natural CD47
ligand, SIRPa. While the mechanism behind this observation is still under
investigation, our preliminary data suggest that it may relate to unique
structural features of CD47 in the human RBC membrane," commented Dr. Uger.
"Importantly, our re sults indicate that our SIRPaFc protein has a preferable
RBC binding profile compared to competing approaches, which we believe may
predict a lower risk of toxicity in patients and a more favorable
pharmacokinetic profile."


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies. The
Company has two premier preclinical programs, a SIRPaFc fusion protein and a
CD200-specific monoclonal antibody (mAb), which target two key immunoregulatory
pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an
antibody-like fusion protein that blocks the activity of CD47, a molecule that
is upregulated on cancer stem cells and bulk tumor cells in acute myeloid
leukemia (AML), and several other tumors. The CD200 mAb is a fully human mAb
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include tigec ycline, which is currently being evaluated in a
multi-centre Phase I study in patients with AML, and TTI-1612, a non-cancer stem
cell asset that has completed a 28-patient Phase I trial in interstitial
cystitis patients. For more information, visit: www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson/Kirin Smith
+1 646-863-6519
jramson@proactivecapital.com
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Apr 2024 to May 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From May 2023 to May 2024